The Microbiome / Microbiota R&D and Business Collaboration Forum
Conference - San Diego, CA, United States
The announcement in June that Johnson & Johnson is collaborating with Second Genome, one of the first biotech companies focused entirely on the human microbiome, is, according to Forbes magazine, a turning point at which “big Pharma” money begins to back this new field of research.
The 1-2 kilograms of bacteria living inside, and on the surface of, all human beings – the Human Microbiome – constitutes both another "human" organ and a third protective "immune system" after the innate and adaptive immune systems. This mix of good and bad bacteria, long a subject of academic interest, has been linked to everything from infectious diseases like clostridium difficile to obesity and even mental health. Now that the commercial potential of this field of research is being recognized it is attracting venture capital and other funding.
Organization: Global Engage
(Courtesy of The Microbiome / Microbiota R&D and Business Collaboration Forum's logo, via gutmicrobiotaforhealth.com)
The Microbiome / Microbiota R&D and Business Collaboration Forum
Mon, Oct 07, 2013 - Tue, Oct 08, 2013
Town and Country Hotel, 500 Hotel Circle North, San Diego, CA 92108, USA
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
